Innate Pharma S.A.
IPHA
$1.36
-$0.06-4.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -0.43% | -31.20% | |||
| Total Other Revenue | -0.43% | -2.16% | |||
| Total Revenue | -0.43% | -12.14% | |||
| Cost of Revenue | -0.43% | 15.96% | |||
| Gross Profit | 0.43% | -24.69% | |||
| SG&A Expenses | -0.43% | 1.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.43% | 11.31% | |||
| Operating Income | 0.43% | -15.79% | |||
| Income Before Tax | 0.43% | -34.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.43% | -34.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.43% | -34.33% | |||
| EBIT | 0.43% | -15.79% | |||
| EBITDA | 0.43% | -13.30% | |||
| EPS Basic | 0.45% | -26.63% | |||
| Normalized Basic EPS | 0.36% | -26.52% | |||
| EPS Diluted | 0.45% | -24.31% | |||
| Normalized Diluted EPS | 0.36% | -26.52% | |||
| Average Basic Shares Outstanding | 0.00% | 6.11% | |||
| Average Diluted Shares Outstanding | 0.00% | 6.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||